Please try another search
For the three months ended 31 March 2022, Genocea Biosciences Inc revenues increased from $0K to $270K. Net loss increased 33% to $16M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and Development - Bal Val increase of 42% to $12.1M (expense), Change in fair value of warrants decrease of 99% to $11K (income).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0.27 | 0 | 1.64 | 0 |
Gross Profit | ||||
Operating Income | -15.77 | -13.41 | -11.72 | -14.55 |
Net Income | -15.98 | -13.28 | -3.62 | -4.31 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 38.79 | 55.97 | 64.92 | 77.38 |
Total Liabilities | 26.4 | 28.89 | 27.09 | 73.33 |
Total Equity | 12.38 | 27.07 | 37.83 | 4.05 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 0 Months | 6 Months |
Cash From Operating Activities | -15.21 | -45.37 | -34.27 | -22.91 |
Cash From Investing Activities | -0.94 | -3.21 | -2.29 | -1.76 |
Cash From Financing Activities | -0.86 | 5.96 | 5.69 | 5.29 |
Net Change in Cash | -17.01 | -42.62 | -30.86 | -19.37 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review